Al White: SightGlass, I think we’re continuing to work on that. We’re moving through the fourth year that clinical data, which we’ll get at later this year, we’ll take a look at it and hopefully get that back in the FDAs hands and knock on wood get approval off that. We still have work to do there. In the meantime, the products launched in several markets around the world. We’re selling that product, as you know, we have great joint venture with EssilorLuxotticaa, a great team there that we’re really, really happy about and excited about. And I think a bright future with that product. I guess what I would say about it right now.
Chris Pasquale: Okay, thanks.
Operator: Our next question comes from the line of Steven Lichtman from Oppenheimer, please proceed.
Steven Lichtman : Thank you. Hi, guys. I was wondering if you could talk on MiSight relative specifically to the U.S. any color you can provide in terms of how that ramp is going, what you’re hearing from customers? Any feedback on that would be helpful?
Al White: Sure. I would say here in the US, it’s kind of the same old, good, strong, consistent performance. It’s not ratcheting up, it hasn’t turned and all of a sudden, we hit a point where it’s escalating higher at a faster trajectory. It’s just good, solid, consistent performance. And we’re seeing that in a number of markets around the world. Now, a lot of markets have much higher incidences of myopia than the U.S. does. But if you’re talking specifically the U.S. market, I would say, good, solid, consistent performance. And I think frankly, that’s what we’re going to continue to see. I mean, as I sit here today, that’s what we’ve seen, which is more independent optometry offices utilizing the product, more retailers buying groups getting in evaluating the product starting to use it. We haven’t hit an inflection point, if you will, where it shoots up, but we certainly have not slowed down on it. So I would just say good, solid, strong, consistent growth.
Steven Lichtman: Got it. Great. And then I think last quarter, you guys talked about some increased investment this year overall on the OpEx line and positives, if you mentioned this already. But is that still consistent this quarter, still expecting an elevated investment on that front? And could you just update us in terms of what some of those investments are?
Al White: Sure, yes. I mean, we’re continuing no question to have investment activity, whether it be infrastructure, the business or whether it’s commercially based around product launches, I mean, obviously, on a product like MyDay Energys, we’re putting the dollars behind the launch on that product. And we’ll continue to do that. When you look at some of the other products we have, MyDay multifocals, we roll it out in different spots around the world, we have promotional campaigns, marketing campaigns supporting those products. So, we’ll continue to do that. I would say we did that in Q1 and we’re going to continue to do that. I think that what Brian’s talked about hear that he’s really spearheaded of driving efficiencies within our business.
That’s a different story. So that’s not a matter of like cutting back on investment activities that we need to do. And that are part of driving the growth of our business that’s about operating our business, or businesses more efficiently than we’ve done in the past. And I think that’s great. And in today’s world, that’s something we have to do. So I can tell you that focus and maybe a relatively newer focus, if you will, within the organization, but a focus within this organization is driving strong, efficient growth.
Steven Lichtman: Got it. Thank you, Al.
Operator: Our final question comes from Navann Ty from BNP Paribas, please proceed.
Navann Ty : Hi, thanks for squeezing me in. My first question is, what is your outlook on OB/GYN in 2023? And do you foresee a sustainable recovery of PARAGARD longer term, and volume market share opportunities, in addition to price increases?
